BioCryst Pharmaceuticals, Inc. (BCRX)
NASDAQ: BCRX · Real-Time Price · USD
8.48
-0.02 (-0.24%)
At close: Mar 6, 2026, 4:00 PM EST
8.60
+0.12 (1.42%)
After-hours: Mar 6, 2026, 7:37 PM EST
BioCryst Pharmaceuticals Stock Forecast
Stock Price Forecast
The 11 analysts that cover BioCryst Pharmaceuticals stock have a consensus rating of "Strong Buy" and an average price target of $20.82, which forecasts a 145.52% increase in the stock price over the next year. The lowest target is $9.00 and the highest is $32.
Price Target: $20.82 (+145.52%)
Analyst Consensus: Strong Buy
* Price targets were last updated on Jan 30, 2026.
Analyst Ratings
The average analyst rating for BioCryst Pharmaceuticals stock is "Strong Buy". This means that analysts believe this stock is likely to perform very well in the near future and significantly outperform the market.
Recommendation Trends
| Rating | Oct '25 | Nov '25 | Dec '25 | Jan '26 | Feb '26 | Mar '26 |
|---|---|---|---|---|---|---|
| Strong Buy | 4 | 4 | 5 | 5 | 5 | 5 |
| Buy | 6 | 6 | 6 | 5 | 5 | 5 |
| Hold | 1 | 1 | 1 | 1 | 1 | 1 |
| Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Strong Sell | 0 | 0 | 0 | 0 | 0 | 0 |
| Total | 11 | 11 | 12 | 11 | 11 | 11 |
Latest Forecasts
| Analyst | Firm | Rating | Rating | Action | Price Target | Upside | Date |
|---|---|---|---|---|---|---|---|
| RBC Capital | RBC Capital | Buy Maintains $14 → $13 | Buy | Maintains | $14 → $13 | +53.30% | Jan 30, 2026 |
| HC Wainwright & Co. | HC Wainwright & Co. | Strong Buy Maintains $30 → $32 | Strong Buy | Maintains | $30 → $32 | +277.36% | Dec 15, 2025 |
| Citizens | Citizens | Buy Maintains $27 → $25 | Buy | Maintains | $27 → $25 | +194.81% | Nov 5, 2025 |
| Barclays | Barclays | Hold Maintains $11 → $9 | Hold | Maintains | $11 → $9 | +6.13% | Nov 4, 2025 |
| Needham | Needham | Strong Buy Maintains $20 → $18 | Strong Buy | Maintains | $20 → $18 | +112.26% | Nov 4, 2025 |
Financial Forecast
Revenue This Year
663.77M
from 874.84M
Decreased by -24.13%
Revenue Next Year
747.06M
from 663.77M
Increased by 12.55%
EPS This Year
0.39
from 1.21
Decreased by -67.50%
EPS Next Year
0.59
from 0.39
Increased by 49.27%
Historical EPS numbers are GAAP, while forecasted numbers may be non-GAAP.
Revenue Forecast
| Revenue | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 695.1M | 841.8M | |||
| Avg | 663.8M | 747.1M | |||
| Low | 627.2M | 672.8M |
Revenue Growth
| Revenue Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -20.5% | 26.8% | |||
| Avg | -24.1% | 12.5% | |||
| Low | -28.3% | 1.4% |
EPS Forecast
| EPS | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | 0.83 | 1.11 | |||
| Avg | 0.39 | 0.59 | |||
| Low | 0.01 | 0.01 |
EPS Growth
| EPS Growth | 2026 | 2027 | 2028 | 2029 | 2030 |
|---|---|---|---|---|---|
| High | -31.2% | 183.1% | |||
| Avg | -67.5% | 49.3% | |||
| Low | -99.2% | -97.5% |
Sources: Price targets and analyst ratings provided by Benzinga. Revenue and EPS forecast data provided by Finnhub. The data is sourced from Wall Street analysts. Data disclaimer.